Ellison Medical Institute and UniQuest enter exclusive license to advance novel prostate cancer therapy toward first-in-human studies
The Ellison Medical Institute has licensed a novel prostate cancer therapy, QED-203, from the University of Queensland. The partnership aims to advance the drug toward first-in-human clinical trials by early 2027.
Why it matters
This development represents a potential breakthrough for patients with metastatic castration-resistant prostate cancer who have exhausted standard treatment options.
LOS ANGELES , June 22, 2026 /PRNewswire/ -- The Ellison Medical Institute (EMI) has entered into an exclusive license with UniQuest, the commercialization company of The University of Queensland (UQ), to advance QED-203, a promising new treatment for advanced and therapy-resistant prostate cancer, toward first-in-human studies.
The text is a standard corporate press release regarding a medical research partnership.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in